Acrivon Therapeutics (NASDAQ:ACRV) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, FiscalAI reports.

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV traded up $0.01 during midday trading on Monday, reaching $1.46. The company had a trading volume of 340,607 shares, compared to its average volume of 791,367. The stock has a market capitalization of $62.57 million, a P/E ratio of -0.78 and a beta of 1.96. The stock’s fifty day moving average price is $1.83 and its 200-day moving average price is $1.75. Acrivon Therapeutics has a one year low of $1.27 and a one year high of $3.56.

Insider Buying and Selling

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen sold 14,036 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the transaction, the chief executive officer directly owned 2,230,052 shares in the company, valued at $4,928,414.92. This represents a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 17,345 shares of company stock worth $37,578. Corporate insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a report on Wednesday, November 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Read Our Latest Research Report on ACRV

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Read More

Earnings History for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.